DOCTORS across Europe are running out of options to treat some serious hospital infections as common bacteria become resistant to key antibiotics, the WHO have warned.
It revealed that in 50% of European countries involved in research, half or more of samples provided of two common hospital borne bacteria were resistant to key antibiotics in an alarming report released in collaboration with the European Centre for Disease Prevention and Control (ECDC).
The organisations are calling for European countries to help combat antimicrobial assistance with urgency as health professionals increasingly turn to broad spectrum beta-lactam antibiotics to tackle bacterial infections previously treatable with standard drugs.
Standard Antibiotic Treatments are Failing
Countries in the World Health Organization’s European Region provided 2025 data from samples of klebsiella pneumoniae, a common hospital bacterium that can cause serious bloodstream infections and Acinetobacter, also found in hospitals.
In 21 of the 43 countries that reported, half or more of the klebsiella pneumoniae, samples tested were resistant to third-generation cephalosporins, or standard antibiotics.
When doctors are unable to treat infections with these types of antibiotics due to resistance, they often turn to carbapenems, antibiotics that work against a wider range of bacteria, according to the report.
However, in some countries, resistance to these second-line options is also increasing with 10 of the reporting countries finding half or more of Klebsiella pneumoniae bacteria resisted carbapenems.
For Acinetobacter, the same was true in 21 of 38 reporting countries.
Dr Marc-Alain Widdowson, Programme Manager, Health Security Division, WHO/Europe, stressed how important these “lines of defence” are.
He said: “In many countries in our Region, the antibiotics doctors usually reach for first are failing against serious hospital infections. So doctors turn to carbapenems, stronger drugs normally kept for the most serious cases.
“When those stop working too, what’s left is mostly a small group of last-resort drugs that are often expensive and not available in every country.”
He added: “That matters, because people whose first antibiotic doesn’t work against their infection are more likely to die in hospital.”
European Countries Missed Targets
To contribute to this growing problem, two of three targets set out by the EU to reduce cases of bloodstream infections caused by resistant bacteria by 2030 are now further from being met than at their starting point in 2019.
Cases of Klebsiella pneumoniae resistant to carbapenems rose by an estimated 75% between 2019 and 2025, significantly failing the target of a 5% fall in infections.
For E. coli, the most common cause of bloodstream infections in the EU, cases resistant to third-generation cephalosporins, a group of commonly used antibiotics, rose by an estimated 16.4%. The target was a 10% fall.
The third target, however, to reduce methicillin-resistant Staphylococcus aureus (MRSA) but 15% was met between 2019 and 2025 with a 19% fall in infections. However, rates of infection have risen in the last 2 years, which may put the target at risk.
Positively, estimated rate of bloodstream infections with resistant Acinetobacter has plummeted by almost 50% since the high levels seen in 2021 during the COVID-19 pandemic.
However, with many countries still lacking a standardised approach to collecting resistance data and the risk to patients that testing treatments that may not work, the full picture is still unclear.
WHO/Europe Calls for Action
Whilst almost every country in the WHO European Region reports having national action plan on antimicrobial resistance or at least revising one, only 40% report carrying it out with funding in place and regular checks on progress.
The WHO/Europe is calling on countries in the Region to commit to funding and executing these national action plans whilst carrying out regular checks and reports on progress.
Infection prevention in hospitals should be treated as a priority so that bacteria is unable to spread from patient to patient, allowing opportunity for resistance to grow during treatment.
When necessary, WHO/Europe advises that antibiotics are used sparingly and as appropriately as possible, allowing for carbapenems and last-resort drugs to be kept for patients who really need them.
Investment in laboratories, including national reference laboratories that can identify how bacteria resist carbapenem, as well as collecting more routine blood cultures so doctors will know what will work before providing treatment, is also encouraged.
Finally, access to last-resort antibiotics should always be available where patients need them.
Dr Widdowson urged countries to act proactively against the threat of spreading resistance. He said: “Nearly every country in our Region has a plan to tackle antimicrobial resistance. Far fewer have the money and follow-through to make it work, and a plan on paper doesn’t stop an infection on a hospital ward.”